New use permitted: FDA approves latanoprost as first-line IOP reducer

Study: Improvements in signs and symptoms of dry eye disease from a single TearCare treatment sustained through 12 Months

Aviceda announces completion of key IND toxicity milestone with positive safety profile in non-human primates

BRIM Biotechnology receives FDA orphan drug designation for treatment of neurotrophic keratitis